Crescents proportions above 10% are associated with unfavorable kidney outcomes in IgA nephropathy patients with partial crescent formation

References

• Nie S, He W, Huang T, et al. The spectrum of biopsy-proven glomerular diseases among children in China: a national, cross-sectional survey. Clin J Am Soc Nephrol. 2018;13(7):1–8. doi: 10.2215/CJN.11461017.
   PubMed Web of Science ®Google Scholar
• Pattrapornpisut P, Avila-Casado C, Reich HN. IgA nephropathy: core curriculum 2021. Am J Kidney Dis. 2021;78(3):429–441. doi: 10.1053/j.ajkd.2021.01.024.
   PubMed Web of Science ®Google Scholar
• Sethi S, De Vriese AS, Fervenza FC. Acute glomerulonephritis. Lancet. 2022;399(10335):1646–1663. doi: 10.1016/S0140-6736(22)00461-5.
   PubMed Web of Science ®Google Scholar
• Roberts ISD. Pathology of IgA nephropathy. Nat Rev Nephrol. 2014;10(8):445–454. doi: 10.1038/nrneph.2014.92.
   PubMed Web of Science ®Google Scholar
• Katafuchi R, Ninomiya T, Nagata M, et al. Validation study of Oxford classification of IgA nephropathy: the significance of extracapillary proliferation. Clin J Am Soc Nephrol. 2011;6(12):2806–2813. doi: 10.2215/CJN.02890311.
   PubMed Web of Science ®Google Scholar
• Trimarchi H. Crescents in primary glomerulonephritis: a pattern of injury with dissimilar actors. A pathophysiologic perspective. Pediatr Nephrol. 2022;37(6):1205–1214. doi: 10.1007/s00467-021-05199-1.
   PubMed Web of Science ®Google Scholar
• Ryu M, Migliorini A, Miosge N, et al. Plasma leakage through glomerular basement membrane ruptures triggers the proliferation of parietal epithelial cells and crescent formation in non-inflammatory glomerular injury: crescents without glomerular inflammation. J Pathol. 2012;228(4):482–494. doi: 10.1002/path.4046.
   PubMed Web of Science ®Google Scholar
• Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int. 2017;91(5):1014–1021. doi: 10.1016/j.kint.2017.02.003.
   PubMed Web of Science ®Google Scholar
• Lv J, Yang Y, Zhang H, et al. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol. 2013;24(12):2118–2125. doi: 10.1681/ASN.2012101017.
   PubMed Web of Science ®Google Scholar
• Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677–686. doi: 10.2215/CJN.07420716.
   PubMed Web of Science ®Google Scholar
• Du Y, Chen S, Wang F, et al. The significance of crescents on the clinical features and outcomes of primary immunoglobin a nephropathy. Front Med. 2022;9:864667. doi: 10.3389/fmed.2022.864667.
   Web of Science ®Google Scholar
• Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–29. doi: 10.1056/NEJMoa1114248.
   PubMed Web of Science ®Google Scholar
• Roberts ISD, Cook HT, Troyanov S, et al. The oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76(5):546–556. HT doi: 10.1038/ki.2009.168.
   PubMed Web of Science ®Google Scholar
• Inker LA, Lambers Heerspink HJ, Mondal H, et al. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials. Am J Kidney Dis. 2014;64(6):848–859. doi: 10.1053/j.ajkd.2014.08.017.
   PubMed Web of Science ®Google Scholar
• Trimarchi H, Haas M, Coppo R. Crescents and IgA nephropathy: a delicate marriage. JCM. 2022;11(13):3569. doi: 10.3390/jcm11133569.
   Google Scholar
• Zhang X, Shi S, Ouyang Y, et al. A validation study of crescents in predicting ESRD in patients with IgA nephropathy. J Transl Med. 2018;16(1):115. doi: 10.1186/s12967-018-1488-5.
   PubMedGoogle Scholar
• Park S, Baek CH, Park S-K, et al. Clinical significance of crescent formation in IgA nephropathy – a multicenter validation study. Kidney Blood Press Res. 2019;44(1):22–32. doi: 10.1159/000497808.
   PubMed Web of Science ®Google Scholar
• Ma F, Liu L, Dong R, et al. Renal survival and risk factors in IgA nephropathy with crescents. Int Urol Nephrol. 2020;52(8):1507–1516. doi: 10.1007/s11255-020-02457-3.
   PubMed Web of Science ®Google Scholar
• Lv J, Shi S, Xu D, et al. Evaluation of the Oxford classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2013;62(5):891–899. doi: 10.1053/j.ajkd.2013.04.021.
   PubMed Web of Science ®Google Scholar
• Haas M, Verhave JC, Liu Z-H, et al. A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol. 2017;28(2):691–701. doi: 10.1681/ASN.2016040433.
   PubMed Web of Science ®Google Scholar
• Ossareh S, Nazemzadeh N, Asgari M, et al. The added value of crescents on Oxford classification score in risk stratification of end-stage kidney disease in patients with IgA nephropathy. Iran J Kidney Dis. 2022;16:115–124. doi: 10.52547/ijkd.6685.
   PubMed Web of Science ®Google Scholar
• Oshima Y, Moriyama T, Itabashi M, et al. Characteristics of IgA nephropathy in advanced-age patients. Int Urol Nephrol. 2015;47(1):137–145. doi: 10.1007/s11255-014-0872-1.
   PubMed Web of Science ®Google Scholar
• Moriyama T, Itabashi M, Takei T, et al. High uric acid level is a risk factor for progression of IgA nephropathy with chronic kidney disease stage G3a. J Nephrol. 2015;28(4):451–456. doi: 10.1007/s40620-014-0154-0.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines—application to the individual patient. Kidney Int. 2012;82(8):840–856. doi: 10.1038/ki.2012.280.
   PubMed Web of Science ®Google Scholar
• Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant. 2003;18(7):1321–1329. doi: 10.1093/ndt/gfg081.
   PubMed Web of Science ®Google Scholar
• Ring T, Pedersen BB, Salkus G, et al. Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? Clin Kidney J. 2015;8(5):489–491. doi: 10.1093/ckj/sfv076.
   PubMedGoogle Scholar
• Xie X, Lv J, Shi S, et al. Plasma exchange as an adjunctive therapy for crescentic IgA nephropathy. Am J Nephrol. 2016;44(2):141–149. doi: 10.1159/000448767.
   PubMed Web of Science ®Google Scholar
• Trivioli G, Canzian A, Maritati F, et al. Renal outcome after rituximab in adult-onset iga vasculitis and crescentic iga nephropathy: a multicentre study. Nephrology Dialysis Transplantation. 2021;36(Supplement_1):gfab117.003. doi: 10.1093/ndt/gfab117.003.
   Google Scholar
• Walsh M, Sar A, Lee D, et al. Histopathologic features aid in predicting risk for progression of IgA nephropathy. Clin J Am Soc Nephrol. 2010;5(3):425–430. doi: 10.2215/CJN.06530909.
   PubMed Web of Science ®Google Scholar
• Coppo R, D’Arrigo G, Tripepi G, et al. Is there long-term value of pathology scoring in immunoglobulin a nephropathy? A validation study of the Oxford classification for IgA nephropathy (VALIGA) update. Nephrol Dial Transplant. 2020;35(6):1002–1009. doi: 10.1093/ndt/gfy302.
   PubMed Web of Science ®Google Scholar
• Shen X-H, Liang S-S, Chen H-M, et al. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation. J Nephrol. 2015;28(4):441–449. doi: 10.1007/s40620-014-0165-x.
   PubMed Web of Science ®Google Scholar
• Jullien P, Laurent B, Berthoux F, et al. Repeat renal biopsy improves the Oxford classification-based prediction of immunoglobulin a nephropathy outcome. Nephrol Dial Transplant. 2020;35(7):1179–1186. doi: 10.1093/ndt/gfy341.
   PubMed Web of Science ®Google Scholar
• Floege J, Barbour SJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2019;95(2):268–280. doi: 10.1016/j.kint.2018.10.018.
   PubMedGoogle Scholar